As of 2026-01-13, the Relative Valuation of Denali Therapeutics Inc (DNLI) is (78.05) USD. This relative valuation is based on P/E multiples. With the latest stock price at 18.11 USD, the upside of Denali Therapeutics Inc based on Relative Valuation is -531.0%.
The range of the Relative Valuation is (69.49) - (76.42) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 18.9x - 23.4x | 21.2x |
| Forward P/E multiples | 21.3x - 32.0x | 26.6x |
| Fair Price | (69.49) - (76.42) | (78.05) |
| Upside | -483.7% - -522.0% | -531.0% |
| Date | P/E |
| 2026-01-12 | -5.50 |
| 2026-01-09 | -5.23 |
| 2026-01-08 | -5.23 |
| 2026-01-07 | -5.19 |
| 2026-01-06 | -5.27 |
| 2026-01-05 | -4.91 |
| 2026-01-02 | -4.98 |
| 2025-12-31 | -5.06 |
| 2025-12-30 | -5.02 |
| 2025-12-29 | -5.08 |
| 2025-12-26 | -5.17 |
| 2025-12-24 | -5.20 |
| 2025-12-23 | -5.15 |
| 2025-12-22 | -5.35 |
| 2025-12-19 | -5.16 |
| 2025-12-18 | -5.14 |
| 2025-12-17 | -5.15 |
| 2025-12-16 | -5.21 |
| 2025-12-15 | -5.31 |
| 2025-12-12 | -5.51 |
| 2025-12-11 | -5.32 |
| 2025-12-10 | -5.38 |
| 2025-12-09 | -6.02 |
| 2025-12-08 | -6.03 |
| 2025-12-05 | -6.11 |
| 2025-12-04 | -6.16 |
| 2025-12-03 | -5.82 |
| 2025-12-02 | -5.46 |
| 2025-12-01 | -5.56 |
| 2025-11-28 | -5.96 |
| 2025-11-26 | -5.94 |
| 2025-11-25 | -5.86 |
| 2025-11-24 | -5.80 |
| 2025-11-21 | -5.51 |
| 2025-11-20 | -5.25 |
| 2025-11-19 | -5.18 |
| 2025-11-18 | -5.35 |
| 2025-11-17 | -5.32 |
| 2025-11-14 | -5.34 |
| 2025-11-13 | -5.25 |
| 2025-11-12 | -5.36 |
| 2025-11-11 | -5.38 |
| 2025-11-10 | -4.78 |
| 2025-11-07 | -4.60 |
| 2025-11-06 | -4.41 |
| 2025-11-05 | -4.56 |
| 2025-11-04 | -4.57 |
| 2025-11-03 | -4.70 |
| 2025-10-31 | -4.99 |
| 2025-10-30 | -5.02 |